Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism CD28 inhibitors(T-cell-specific surface glycoprotein CD28 inhibitors), PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Preclinical | CN | 22 Mar 2024 |